MedTrace Logo

HDL-C in Cardiac Syndrome X

NCT02095964 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 710

Last updated 2014-03-26

No results posted yet for this study

Summary

High density lipoprotein cholesterol (HDL-C) is in the centrum of the process of reverse cholesterol transport from peripheral cells to the liver\[10\]. HDL-C promotes endothelial generation of nitric oxide (NO) and improves endothelial function and arterial vasoreactivity\[11\]. In several studies, lower HDL-C level was reported to be associated with increased coronary artery disease (CAD) risk\[12-14\]. HDL-C also has anti- inflammatory and anti-oxidant activities\[15,16\]. Concerning anti-inflammatory activity, HDL-C inhibits the activation of monocytes/macrophages and neutrophils\[17,18\] and inhibits the expression of endothelial adhesion molecules, such as vascular cell adhesion molecule-1 (VCAM-1) and E-selectin\[15\].

In this study we aimed to investigate the relation of HDL-C level with systemic inflammatory markers in patients with cardiac syndrome X (CSX).

Conditions

Sponsors & Collaborators

  • Bursa Yuksek Ihtisas Training and Research Hospital

    lead OTHER_GOV

Eligibility

Min Age
47 Years
Max Age
58 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-03-31
Primary Completion
2013-12-31
Completion
2014-01-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02095964 on ClinicalTrials.gov